UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043313
Receipt number R000049439
Scientific Title Imaging evaluation of estrogen receptor in breast cancer
Date of disclosure of the study information 2021/02/16
Last modified on 2022/02/06 15:42:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Imaging evaluation of estrogen receptor in breast cancer

Acronym

Imaging evaluation of estrogen receptor in breast cancer

Scientific Title

Imaging evaluation of estrogen receptor in breast cancer

Scientific Title:Acronym

Imaging evaluation of estrogen receptor in breast cancer

Region

Japan


Condition

Condition

Breast cancer

Classification by specialty

Breast surgery Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the predictive values of [18F]fluoroestradiol ([18F]FES) PET for treatment efficacy and its prognostic impact in patients with breast cancer

Basic objectives2

Others

Basic objectives -Others

In this study, estrogen receptor expression status will be evaluated by [18F]FES-PET using PET/CT, dedicated breast PET, and PET/MRI, and its performance in the prediction of therapeutic effect and the patient prognosis will be examined. Comparison among PET systems and optimization of imaging methods, verification of pathological and clinical features related to [18F]FES accumulation, and construction of a diagnostic algorithm with other diagnostic examinations for breast cancer are included.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Qualitative and quantitative parameters of [18F]FES-PET will be correlated with patient prognosis, and with the therapeutic effects measured by image monitoring or pathological evaluation.

Key secondary outcomes

- Comparison among PET systems and optimization of examination methods and image reconstruction parameters
- Verification of pathological and clinical features related to [18F]FES accumulation
- Comparison and validation with existing diagnostic examinations for breast cancer
- Construction of a diagnostic algorithm using a multi-marker approach combining multiple tests


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine Device,equipment

Interventions/Control_1

About 1-1.5 hr after [18F]FES injection (approximately 111-222 MBq), PET/CT, dedicated breast PET, and/or PET/MR scanning will be performed. A small amount of blood will be collected at the time of [18F]FES injection.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients over 20 years of age at the time of consent
2. Patients who have been diagnosed with breast cancer or have a strong clinical or imaging suspicion of breast cancer.
3. Patients who have completed the written informed consent

Key exclusion criteria

1. Patients who received selective estrogen receptor modulators (SERMs) or selective estrogen down regulators (SERDs) within 5 weeks prior to [18F] FES-PET
2. Patient who had adverse reactions to [18F]FES in the past
3. Women who are or may be pregnant
4. Patients in extremely poor general condition
5. Patients with significant communication difficulties
6. Patients judged not to be appropriate for attending this study by investigators

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Yuji
Middle name
Last name Nakamoto

Organization

Kyoto University Hospital

Division name

Department of Diagnostic Imaging and Nuclear Medicine

Zip code

606-8507

Address

54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto

TEL

075-751-3760

Email

ynakamo1@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name Kanae
Middle name Kawai
Last name Miyake

Organization

Kyoto University Graduate School of Medicine

Division name

Department of Advanced Medical Imaging Research

Zip code

606-8507

Address

54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto-city

TEL

075-751-3760

Homepage URL


Email

kanaek@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Kyoto University

Institute

Department

Personal name



Funding Source

Organization

Japan Science and Technology Agency (JST)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto University Graduate School and Faculty of Medicine, Ethics Committee

Address

Yoshida-Konoe-cho, Sakyo-ku, Kyoto

Tel

075-753-4680

Email

ethcom@kuhp.kyoto-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2021 Year 01 Month 14 Day

Date of IRB

2021 Year 01 Month 14 Day

Anticipated trial start date

2021 Year 02 Month 22 Day

Last follow-up date

2033 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 02 Month 12 Day

Last modified on

2022 Year 02 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049439


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name